Key Events This Week
27 Jan: Stock opens strong at Rs.750.20 (+3.28%)
29 Jan: Q3 FY26 results reveal profit surge; upgraded to Strong Buy; bullish technical momentum
30 Jan: Hits upper circuit at Rs.818.00 (+4.67%) on robust buying
27 January: Strong Opening Amid Positive Market Sentiment
Venus Remedies commenced the week on a positive note, closing at Rs.750.20, up 3.28% from the previous Friday’s close of Rs.726.40. This gain outpaced the Sensex’s 0.50% rise to 35,786.84, signalling early investor enthusiasm. The volume of 2,878 shares indicated moderate participation, setting the tone for the week’s upward momentum.
28 January: Continued Gains Supported by Market Rally
The stock extended its gains to Rs.760.05, a 1.31% increase over the prior day, while the Sensex surged 1.12% to 36,188.16. Despite a lower volume of 1,497 shares, Venus Remedies maintained its outperformance, reflecting sustained buying interest amid a broadly bullish market environment.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
29 January: Stellar Q3 Results and Strong Buy Upgrade Propel Stock
Venus Remedies posted exceptional Q3 FY26 results, reporting a staggering net profit growth of 473.5% and a six-month PAT of ₹29.73 crores, up 528.54% year-on-year. Profit before tax excluding other income soared by 2073.68% to ₹24.78 crores, underscoring operational efficiency despite some margin volatility. These results were a catalyst for the MarketsMOJO upgrade of the stock’s rating from 'Buy' to 'Strong Buy' with a Mojo Score of 80.0, reflecting robust fundamentals and technical strength.
The stock closed at Rs.784.65, up 3.24%, outperforming the Sensex’s modest 0.22% gain. Technical indicators showed a marked shift to bullish momentum, with MACD bullish on weekly and monthly charts, daily moving averages confirming an uptrend, and Bollinger Bands signalling strong buying interest. However, mixed signals from the monthly RSI and volume-based indicators suggested some caution over longer-term momentum.
Delivery volumes rose by 21.53% compared to the five-day average, indicating increased investor commitment. The stock traded within a range of Rs.740.30 to Rs.778.00, closing near the day’s high, reflecting strong demand.
30 January: Upper Circuit Surge Highlights Robust Buying Momentum
Venus Remedies capped the week with a dramatic 4.67% gain, closing at Rs.818.15 after hitting the upper circuit limit of 5%. The intraday high reached Rs.820.55, with total traded volume of approximately 41,955 shares and turnover of ₹3.43 crore. This surge was driven by strong investor participation and a supply-demand imbalance, resulting in a regulatory freeze on further price movement.
The stock outperformed its Pharmaceuticals & Biotechnology sector, which gained 0.56%, and the Sensex, which declined 0.22%. Trading comfortably above all key moving averages, Venus Remedies demonstrated strong technical resilience. The current price is just 2.68% below its 52-week high of Rs.839.90, signalling proximity to a critical resistance level.
While the upper circuit reflects bullish sentiment, investors should be mindful of potential volatility once trading restrictions lift. The stock’s market capitalisation stands at ₹1,049 crore, categorising it as a micro-cap, with a strong mojo grade reinforcing positive analyst sentiment.
Venus Remedies Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this micro-cap stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth micro-cap analysis
- - Valuation assessment included
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-01-27 | Rs.750.20 | +3.28% | 35,786.84 | +0.50% |
| 2026-01-28 | Rs.760.05 | +1.31% | 36,188.16 | +1.12% |
| 2026-01-29 | Rs.784.65 | +3.24% | 36,266.59 | +0.22% |
| 2026-01-30 | Rs.818.15 | +4.27% | 36,185.03 | -0.22% |
Key Takeaways
Positive Signals: Venus Remedies demonstrated exceptional profit growth with a 473.5% surge in net profit for Q3 FY26, underpinning the stock’s strong fundamentals. The upgrade to a 'Strong Buy' rating with a Mojo Score of 80.0 reflects improved financial quality, valuation, and technical momentum. The stock consistently outperformed the Sensex throughout the week, culminating in an upper circuit surge that highlights robust investor demand. Technical indicators such as bullish MACD, moving averages, Bollinger Bands, and KST across multiple timeframes support sustained upward momentum.
Cautionary Notes: Despite the strong rally, mixed signals from the monthly RSI and volume-based indicators suggest some caution over longer-term momentum. The upper circuit freeze indicates a temporary supply shortage but also raises the possibility of volatility once trading resumes. As a micro-cap stock, Venus Remedies remains susceptible to liquidity-driven price swings and sector-specific risks inherent in Pharmaceuticals & Biotechnology.
Conclusion
Venus Remedies Ltd’s 12.63% weekly gain, significantly outperforming the Sensex’s 1.62%, was driven by a confluence of strong quarterly results, a decisive upgrade to a 'Strong Buy' rating, and a pronounced shift to bullish technical momentum. The stock’s surge to the upper circuit on 30 January 2026 underscores robust buying interest and investor confidence. While some technical indicators advise caution, the overall outlook remains positive, supported by solid fundamentals and growing institutional participation. Investors should monitor volume trends and price action closely as the stock approaches its 52-week high and navigates potential volatility in the coming sessions.
Unlock special upgrade rates for a limited period. Start Saving Now →
